top of page

Miro Sciences (ASX MSX), Research and Coverage

miro-sciences-ltd

Miro Sciences Ltd (ASX: MSX), formerly NeuroScientific Biopharmaceuticals Ltd (ASX: NSB), is a Perth biotechnology company. It changed its name and ASX code on 28 October 2026 (ASX announcement, 28 October 2026). It is developing StemSmart, a cell therapy made from donor stem cells, for Crohn's disease that has not responded to approved drugs. In its Special Access Program, 4 of 5 patients met the company's definition of a clinical response, with no serious adverse events (ASX announcement, 26 May 2026). The loss was A$4.69 million in the year to 30 June 2026 (annual report, lodged 25 August 2026). Cash was A$3.91 million at 30 September 2026 (Appendix 4C, lodged 27 October 2026). Samso had published 3 pieces on the company at 19 November 2026.

ASX code: MSX. Full legal name: Miro Sciences Ltd. Chief Executive Officer: Nathan Smith. Non-Executive Chairman: Robert McKenzie. The other board members are Paul Fry, Clarke Barlow and Dr Anton Uvarov, all non-executive directors. Nathan Smith is not a director (ASX company data, read 19 November 2026, and annual report, lodged 25 August 2026). Cash was A$3.91 million at 30 September 2026, and the company reported no loan facilities (quarterly report and Appendix 4C, lodged 27 October 2026).

The company was called NeuroScientific Biopharmaceuticals Ltd until 28 October 2026. Shareholders approved the new name at the annual general meeting on 15 October 2026. The ASX code changed from NSB to MSX from the start of trading on 28 October 2026 (ASX announcement, 28 October 2026). The company says the new name reflects its focus on StemSmart and Crohn's disease. Every Samso piece listed below was published under the former name.

What Miro Sciences is developing

Miro Sciences is developing StemSmart, a cell therapy made from mesenchymal stem cells, or MSCs. These are adult stem cells taken from donor bone marrow. StemSmart cells are grown with a patented manufacturing process developed at Royal Perth Hospital. The company says the process is designed to improve the cells' therapeutic activity and clinical response, and to regulate harmful immune responses often linked to severe and chronic inflammation (ASX announcement, 12 November 2026).

The company bought StemSmart by acquiring all of Isopogen WA Ltd, a deal that completed on 27 June 2025. Part of the price was 57,142,841 performance shares, which convert to ordinary shares when a set milestone is met. They converted on 1 June 2026 after the Special Access Program met its milestone (annual report, note 14, lodged 25 August 2026). Robert McKenzie, Paul Fry and Dr Marian Sturm received performance shares as Isopogen shareholders (annual report, remuneration report). Dr Sturm invented the technology and is Chief Scientific Officer (ASX announcement, 12 November 2026).

The first target is refractory Crohn's disease. Crohn's disease is a long-term inflammation of the gut. Refractory means it has not responded to approved drugs. The company has also treated fistulising Crohn's disease, where abnormal channels called fistulas form from the bowel (ASX announcement, 26 May 2026).

The earlier asset was EmtinB, a peptide the company was developing for glaucoma, an eye disease. After a strategic review the board decided not to continue developing EmtinB itself. It is seeking to license EmtinB to another company or find a partner. It wrote the licence's value in its accounts down to nil (annual report, lodged 25 August 2026).

StemSmart results so far

The company cites a published Phase 2 trial in 18 patients with Crohn's disease who had failed anti-TNF drugs, a common class of biologic medicine. The trial was open-label, meaning patients and doctors knew the treatment. Patients received four weekly infusions. At day 42, 14 of 18 (78 per cent) had a clinical response. Clinical response meant a fall of more than 100 points in the Crohn's Disease Activity Index, a standard symptom score. The company says the treatment was well tolerated, with one serious adverse event that it describes as unrelated to the cells (company presentation, lodged 5 November 2026, citing the announcement of 16 April 2025).

The newer evidence comes from a Special Access Program. The Therapeutic Goods Administration, or TGA, is Australia's medicines regulator. Its Special Access Scheme lets a doctor apply to give an unapproved medicine to one patient. Each patient in the program was approved by the TGA under the scheme's Category B pathway, where the TGA reviews each application (ASX announcement, 26 May 2026).

In January 2026 the company reported that 3 of the first 4 patients had a clinical response and the fourth had a partial response (ASX announcement, 13 January 2026). On 26 May 2026 it reported the completed program. Of five patients aged 18 to 49, four (80 per cent) had a clinical response and all five improved. A clinical response was closure of at least half of the fistula openings, or at least a halving of fistula discharge, as assessed by the treating doctor or a qualified investigator. All patients had at least one seton removed. A seton is a surgical drain placed in a fistula. No serious adverse events were observed (ASX announcement, 26 May 2026).

The company describes both sets of StemSmart data as open-label. It says its planned Phase 2 trial is designed to confirm this signal against placebo (company presentation, lodged 5 November 2026).

Miro Sciences Phase 2 trial plans

Miro Sciences is preparing a Phase 2 trial of StemSmart in refractory Crohn's disease in Australia and the United States. A Phase 2 trial tests whether a treatment works in a larger group than earlier studies. The draft design is randomised and placebo-controlled. About 74 patients who have failed at least two biologic or other advanced therapies would be split equally between StemSmart and placebo. The primary endpoints, the main measures the trial is built to test, are safety and clinical response against placebo at week 11. The design is subject to ethics and regulatory approval (company presentation, lodged 5 November 2026).

On 13 October 2026 the company reported on a Pre-IND meeting with the United States Food and Drug Administration, or FDA. An IND is the application the FDA requires before a new drug is tested in people in the United States. A Pre-IND meeting gives early guidance on it. The company says the FDA gave positive responses to 6 of its 7 questions. These included agreement with the trial design and that no further non-clinical studies were needed. The outstanding item was the manufacturing control strategy, to make sure the product is free of viral contamination. The company says it is adding that testing with minimal impact on timing (ASX announcement, 13 October 2026).

The company appointed Southern Star Research as its clinical research organisation on 1 October 2026. This is the firm that will set up and manage the trial sites (ASX announcement, 1 October 2026).

Manufacturing is being transferred to Q-Gen Cell Therapeutics in Brisbane, which holds a TGA licence for cell therapy manufacture. On 12 November 2026 the company announced that the TGA had completed its inspection of Q-Gen for StemSmart manufacturing. It describes this as a major step towards supplying StemSmart for the Phase 2 trial (ASX announcement, 12 November 2026). The inspection is for an extension of Q-Gen's TGA licence to cover StemSmart, which the company expected before the end of 2026 (quarterly report, lodged 27 October 2026). No licence decision had been announced at 19 November 2026.

Miro Sciences is targeting the start of the trial by the end of 2026, subject to regulatory, manufacturing and operational requirements (ASX announcement, 13 October 2026). Its presentation lists a first Australian patient in the first quarter of 2027 and an IND submission in the second quarter of 2027 (company presentation, lodged 5 November 2026).

Miro Sciences has also described a trial in fistulising Crohn's disease. On 26 May 2026 it said it had begun developing a separate Australia-only Phase 2 trial in that condition (ASX announcement, 26 May 2026). Its quarterly report describes an open-label early phase trial in fistulising Crohn's disease, with plans still being determined (quarterly report, lodged 27 October 2026).

Miro Sciences cash and funding

Miro Sciences has no product sales. It reported a loss after tax of A$4.69 million in the year to 30 June 2026, against A$1.85 million a year earlier. Income of A$629,398 was mainly a research and development tax incentive refund of A$402,659. Net cash used in operations was A$2.78 million (annual report, lodged 25 August 2026).

At 30 June 2026 the company held A$2.63 million in cash and A$2.0 million in term deposits, A$4.63 million together. Total liabilities were A$374,890, made up of payables, employee benefits and lease liabilities. The balance sheet shows no borrowings. Net assets were A$14.81 million, including A$10.27 million of intangible assets (annual report, lodged 25 August 2026).

The accounts were prepared on a going concern basis, the assumption that a company can keep operating and pay its debts as they fall due. The directors were satisfied the group would have enough cash to fund forecast spending for at least twelve months from the date of the report. The auditor listed going concern, under the heading future funding, as a key audit matter, one of the matters most significant to its audit. Its report has no material uncertainty section (annual report, lodged 25 August 2026).

In the September quarter, net cash used in operating activities was A$719,000, including A$409,000 on research and development. The Appendix 4C gives 5.44 quarters of funding, which is quarter-end cash divided by that quarter's operating cash outflow (quarterly report and Appendix 4C, lodged 27 October 2026).

There were 389,718,547 shares on issue at 31 July 2026, plus 43,250,000 unlisted options. Of those shares, 75,646,442 are held in escrow, meaning they cannot be sold, until 27 March 2027. The largest holder was Sturm West Pty Ltd (The Callahan Family A/C), with 10.60 per cent. Paul Fry and Gillian Evans were listed together as a substantial holder, with 5.77 per cent (annual report, shareholder information at 31 July 2026).

Every Samso piece on Miro Sciences and NeuroScientific

3 published pieces as at 19 November 2026, grouped by Samso product. Newest first in each group. Dates are Perth dates.

Samso News

Questions people ask about Miro Sciences (ASX MSX)

What happened to NeuroScientific Biopharmaceuticals (ASX NSB)? It changed its name to Miro Sciences and its ASX code to MSX on 28 October 2026 (ASX announcement, 28 October 2026). Miro Sciences is developing StemSmart, a donor stem cell therapy, for Crohn's disease that has not responded to approved drugs.

What is the Miro Sciences share price? The ASX website shows the MSX share price. This page lists Samso's coverage and has no live price.

What is the latest announcement from Miro Sciences? As at 19 November 2026 the newest item on the ASX list was the completion of the TGA inspection of its manufacturing partner Q-Gen, lodged on 12 November 2026.

Is Miro Sciences worth looking at? This page gives no buy, sell or hold call, price target or valuation. Miro Sciences has StemSmart results from an earlier Phase 2 trial and a Special Access Program. The company says the FDA gave positive responses to 6 of its 7 Pre-IND questions. Its placebo-controlled Phase 2 trial design is subject to ethics and regulatory approval (company presentation, lodged 5 November 2026). No trial start had been announced by 19 November 2026. Miro Sciences has no product sales and reported a loss of A$4.69 million in the year to 30 June 2026. Samso had published no research workup on Miro Sciences at 19 November 2026.

Disclosure

Samso holds no shares in Miro Sciences at 17 November 2026.

This page is general information only.

Depth over hype.

Samso company research pages are independent research commentary for general information only. Nothing on this page is financial product advice, and it does not take into account any reader's objectives, financial situation or needs. Figures are drawn from public sources believed reliable at the stated dates but are not guaranteed, and market-sensitive numbers change daily. Samso or associated parties may hold positions in, or have commercial arrangements with, companies mentioned. Seek professional advice before making investment decisions. © Samso 2026, samso.com.au

Page last reviewed 19 November 2026.

bottom of page